These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22924678)

  • 61. Reasons for nonadherence and response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients.
    Schoor R; Bruce A; Bruce J; Goggin K; Schanfarber B; Bradley-Ewing A; Thelen J; Glusman M; Lynch SG; Strober L; Catley D
    J Clin Psychol; 2019 Mar; 75(3):380-391. PubMed ID: 30485422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis.
    Stratos K; McGarragle K; Thistle J; Vyas MV; Lee L
    Mult Scler Relat Disord; 2020 Jun; 41():102016. PubMed ID: 32135497
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.
    Calocer F; Dejardin O; Droulon K; Launoy G; Defer G
    PLoS One; 2018; 13(2):e0191646. PubMed ID: 29390025
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).
    Patti F; Chisari CG; D'Amico E; Annovazzi P; Banfi P; Bergamaschi R; Clerici R; Conti MZ; Cortese A; Fantozzi R; Fischetti M; Frigo M; Gatto M; Immovilli P; Leoni S; Malucchi S; Maniscalco G; Marfia GA; Paolicelli D; Perini P; Serrati C; Sola P; Totaro R; Turano G; Valentino P; Zaffaroni M; Zuliani C; Centonze D
    Mult Scler Relat Disord; 2020 Jul; 42():102124. PubMed ID: 32353755
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study.
    Arroyo R; Sempere AP; Ruiz-Beato E; Prefasi D; Carreño A; Roset M; Maurino J
    BMJ Open; 2017 Mar; 7(3):e014433. PubMed ID: 28274968
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.
    Chouhfeh L; Kavak KS; Teter BE; Weinstock-Guttman B
    Mult Scler Relat Disord; 2015 May; 4(3):228-33. PubMed ID: 26008939
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).
    Dobson R; Craner M; Waddingham E; Miller A; Pindoria J; Cavey A; Blain C; De Luca G; Evangelou N; Ford H; Gallagher P; George K; Geraldes Ramos Dias R; Harman P; Hobart J; King T; Linighan R; MacDougall N; Marta M; Mitchell S; Nicholas R; Rog D; Scalfari A; Scolding N; Webb S; White S; Wilton J; Young C; Matthews PM
    Mult Scler Relat Disord; 2022 Jul; 63():103894. PubMed ID: 35636271
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
    Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
    Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.
    Neter E; Glass-Marmor L; Wolkowitz A; Lavi I; Miller A
    BMC Neurol; 2021 Mar; 21(1):136. PubMed ID: 33761887
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Stopping immunomodulatory medications in MS: Frequency, reasons and consequences.
    Tobin WO; Weinshenker BG
    Mult Scler Relat Disord; 2015 Sep; 4(5):437-443. PubMed ID: 26346792
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Exacerbation history is associated with medication and appointment adherence in MS.
    Hancock LM; Bruce JM; Lynch SG
    J Behav Med; 2011 Oct; 34(5):330-8. PubMed ID: 21259038
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association Between Body Mass Index and Response to Disease-Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis at King Abdulaziz University Hospital: A Retrospective Study.
    Aljehani MN; Alshehri ZI; Alharbi FA; Balbaid YT; Wali AM; Alotaibi AA
    Cureus; 2022 Dec; 14(12):e32695. PubMed ID: 36545354
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.
    Nguyen AL; Havrdova EK; Horakova D; Izquierdo G; Kalincik T; van der Walt A; Terzi M; Alroughani R; Duquette P; Girard M; Prat A; Boz C; Sola P; Ferraro D; Lugaresi A; Lechner-Scott J; Barnett M; Grand'Maison F; Grammond P; Ramo-Tello C; Turkoglu R; McCombe P; Pucci E; Trojano M; Granella F; Spitaleri D; Van Pesch V; Soysal A; Oreja-Guevara C; Verheul F; Vucic S; Hodgkinson S; Slee M; Ampapa R; Prevost J; Menoyo JLS; Skibina O; Solaro C; Olascoaga J; Shaw C; Madsen KG; Naidoo K; Hyde R; Butzkueven H; Jokubaitis V;
    Mult Scler Relat Disord; 2019 Feb; 28():235-243. PubMed ID: 30623864
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.
    Monschein T; Salhofer-Polanyi S; Altmann P; Zrzavy T; Dal-Bianco A; Bsteh G; Rommer P; Berger T; Leutmezer F
    J Neurol; 2021 Apr; 268(4):1247-1253. PubMed ID: 32929591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. "I'm walking into the unknown": Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment.
    Carey G; Wilson N; Janssen J; Chohan A; Rog D; Roddam H
    Mult Scler Relat Disord; 2022 Feb; 58():103464. PubMed ID: 34952250
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI-CBT intervention.
    Thelen J; Bruce A; Catley D; Lynch S; Goggin K; Bradley-Ewing A; Glusman M; Norouzinia A; Strober L; Bruce J
    J Behav Med; 2018 Apr; 41(2):253-260. PubMed ID: 29124557
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The impact of comorbid depression on adherence to therapy for multiple sclerosis.
    Tarrants M; Oleen-Burkey M; Castelli-Haley J; Lage MJ
    Mult Scler Int; 2011; 2011():271321. PubMed ID: 22096632
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy].
    Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):86-93. PubMed ID: 31156246
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Impact of Stopping Medications and Introducing a Whole Food Plant-Based Diet on Patients Living with Multiple Sclerosis - A Report of Two Cases.
    Cuthbert M; Lewandowska M; Freeman L; Devine C; Lee K; Kassam S
    Am J Lifestyle Med; 2023; 17(2):206-212. PubMed ID: 36896042
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling.
    Soini E; Holmberg M; Asseburg C; Sumelahti ML
    Value Health; 2014 Nov; 17(7):A400. PubMed ID: 27200954
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.